Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Todd Neale

September 01, 2025

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Todd Neale

September 02, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

Advertisement

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

CV Care Around Noncardiac Surgery: New ESC Guidelines

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Observational Study Supports Continuing Oral Anticoagulation During PCI

Roughly 80% of ESC Guideline Writers Have Financial COIs

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

TCTMD’s Top 10 Most Popular Stories for June 2019

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

ESC Updates Guidelines for Treating STEMI Patients

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content